Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

BACKGROUND: Vericiguat, a stimulator of soluble guanylate cyclase, has been developed as a first-in-class therapy for worsening chronic heart failure in adults with left ventricular ejection fraction < 45%. OBJECTIVE: The objective of this article was to characterize the pharmacokinetics and phar...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruehs, Hauke, Klein, Dagmar, Frei, Matthias, Grevel, Joachim, Austin, Rupert, Becker, Corina, Roessig, Lothar, Pieske, Burkert, Garmann, Dirk, Meyer, Michaela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585847/
https://www.ncbi.nlm.nih.gov/pubmed/34086190
http://dx.doi.org/10.1007/s40262-021-01024-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585847/
https://www.ncbi.nlm.nih.gov/pubmed/34086190
http://dx.doi.org/10.1007/s40262-021-01024-y

Ejemplares similares